1. Home
  2. INZY vs BW Comparison

INZY vs BW Comparison

Compare INZY & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INZY
  • BW
  • Stock Information
  • Founded
  • INZY 2015
  • BW 1867
  • Country
  • INZY United States
  • BW United States
  • Employees
  • INZY N/A
  • BW N/A
  • Industry
  • INZY Biotechnology: Pharmaceutical Preparations
  • BW Building Products
  • Sector
  • INZY Health Care
  • BW Industrials
  • Exchange
  • INZY Nasdaq
  • BW Nasdaq
  • Market Cap
  • INZY 188.2M
  • BW 182.0M
  • IPO Year
  • INZY 2020
  • BW N/A
  • Fundamental
  • Price
  • INZY $1.36
  • BW $1.39
  • Analyst Decision
  • INZY Strong Buy
  • BW Strong Buy
  • Analyst Count
  • INZY 8
  • BW 3
  • Target Price
  • INZY $17.75
  • BW $4.50
  • AVG Volume (30 Days)
  • INZY 1.0M
  • BW 1.1M
  • Earning Date
  • INZY 03-11-2025
  • BW 03-13-2025
  • Dividend Yield
  • INZY N/A
  • BW N/A
  • EPS Growth
  • INZY N/A
  • BW N/A
  • EPS
  • INZY N/A
  • BW N/A
  • Revenue
  • INZY N/A
  • BW $878,224,000.00
  • Revenue This Year
  • INZY N/A
  • BW N/A
  • Revenue Next Year
  • INZY N/A
  • BW N/A
  • P/E Ratio
  • INZY N/A
  • BW N/A
  • Revenue Growth
  • INZY N/A
  • BW N/A
  • 52 Week Low
  • INZY $1.24
  • BW $0.75
  • 52 Week High
  • INZY $7.80
  • BW $2.99
  • Technical
  • Relative Strength Index (RSI)
  • INZY 29.28
  • BW 40.89
  • Support Level
  • INZY $1.35
  • BW $1.27
  • Resistance Level
  • INZY $1.62
  • BW $1.43
  • Average True Range (ATR)
  • INZY 0.13
  • BW 0.10
  • MACD
  • INZY 0.04
  • BW -0.00
  • Stochastic Oscillator
  • INZY 32.89
  • BW 33.72

About INZY Inozyme Pharma Inc.

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: